Magnetic resonance imaging identifies differential response to pro-oxidant chemotherapy in a xenograft model

Terry H Landowski, Gerald P. Guntle, Dezheng Zhao, Bhumasamudram Jagadish, Eugene A Mash, Robert T Dorr, Natarajan Raghunand

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Induction of oxidative stress is a key component of cancer therapy. Pro-oxidant drugs have been demonstrated to enhance the efficacy of radiotherapy and chemotherapy. An emerging concept is that therapeutic outcomes are dictated by the differential redox buffering reserve in subpopulations of malignant cells, indicating the need for noninvasive biomarkers of tumor redox that can be used for dose identification and response assessment in a longitudinal setting. Magnetic resonance imaging (MRI) enhanced with the thiol-binding contrast agent Gd-LC6-SH, and hemodynamic response imaging (HRI) in combination with hypercapnia and hyperoxia were investigated as biomarkers of the pharmacodynamics of the small molecule pro-oxidant imexon (IMX). Human multiple myeloma cell lines 8226/S and an IMX-resistant variant, 8226/IM10, were established as contralateral tumors in SCID mice. T1slope, an MRI measure of the washout rate of Gd-LC6-SH, was significantly lower post-IMX therapy in 8226/S tumors compared with vehicle controls, indicating treatment-related oxidization of the tumor microenvironment, which was confirmed by analysis of tumor tissue for thiols. T1slope and ex vivo assays for thiols both indicated a more reduced microenvironment in 8226/IM10 tumors following IMX therapy. HRI with hypercapnia challenge revealed IMX inhibition of vascular dilation in 8226/S tumors but not 8226/IM10 tumors, consistent with decreased immunohistochemical staining for smooth muscle actin in treated 8226/S tumors. MRI enhanced with Gd-LC6-SH, and HRI coupled with a hypercapnic challenge provide noninvasive biomarkers of tumor response to the redox modulator imexon.

Original languageEnglish (US)
Pages (from-to)228-235
Number of pages8
JournalTranslational Oncology
Volume9
Issue number3
DOIs
StatePublished - Jun 1 2016

Fingerprint

Heterografts
Reactive Oxygen Species
Magnetic Resonance Imaging
Drug Therapy
Neoplasms
Sulfhydryl Compounds
Oxidation-Reduction
Hypercapnia
Hemodynamics
Tumor Biomarkers
Therapeutics
Hyperoxia
Tumor Microenvironment
SCID Mice
Prodrugs
Multiple Myeloma
Contrast Media
Smooth Muscle
Blood Vessels
4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Magnetic resonance imaging identifies differential response to pro-oxidant chemotherapy in a xenograft model. / Landowski, Terry H; Guntle, Gerald P.; Zhao, Dezheng; Jagadish, Bhumasamudram; Mash, Eugene A; Dorr, Robert T; Raghunand, Natarajan.

In: Translational Oncology, Vol. 9, No. 3, 01.06.2016, p. 228-235.

Research output: Contribution to journalArticle

Landowski, Terry H ; Guntle, Gerald P. ; Zhao, Dezheng ; Jagadish, Bhumasamudram ; Mash, Eugene A ; Dorr, Robert T ; Raghunand, Natarajan. / Magnetic resonance imaging identifies differential response to pro-oxidant chemotherapy in a xenograft model. In: Translational Oncology. 2016 ; Vol. 9, No. 3. pp. 228-235.
@article{af2054594cd1446993d4c0f47fcb30c1,
title = "Magnetic resonance imaging identifies differential response to pro-oxidant chemotherapy in a xenograft model",
abstract = "Induction of oxidative stress is a key component of cancer therapy. Pro-oxidant drugs have been demonstrated to enhance the efficacy of radiotherapy and chemotherapy. An emerging concept is that therapeutic outcomes are dictated by the differential redox buffering reserve in subpopulations of malignant cells, indicating the need for noninvasive biomarkers of tumor redox that can be used for dose identification and response assessment in a longitudinal setting. Magnetic resonance imaging (MRI) enhanced with the thiol-binding contrast agent Gd-LC6-SH, and hemodynamic response imaging (HRI) in combination with hypercapnia and hyperoxia were investigated as biomarkers of the pharmacodynamics of the small molecule pro-oxidant imexon (IMX). Human multiple myeloma cell lines 8226/S and an IMX-resistant variant, 8226/IM10, were established as contralateral tumors in SCID mice. T1slope, an MRI measure of the washout rate of Gd-LC6-SH, was significantly lower post-IMX therapy in 8226/S tumors compared with vehicle controls, indicating treatment-related oxidization of the tumor microenvironment, which was confirmed by analysis of tumor tissue for thiols. T1slope and ex vivo assays for thiols both indicated a more reduced microenvironment in 8226/IM10 tumors following IMX therapy. HRI with hypercapnia challenge revealed IMX inhibition of vascular dilation in 8226/S tumors but not 8226/IM10 tumors, consistent with decreased immunohistochemical staining for smooth muscle actin in treated 8226/S tumors. MRI enhanced with Gd-LC6-SH, and HRI coupled with a hypercapnic challenge provide noninvasive biomarkers of tumor response to the redox modulator imexon.",
author = "Landowski, {Terry H} and Guntle, {Gerald P.} and Dezheng Zhao and Bhumasamudram Jagadish and Mash, {Eugene A} and Dorr, {Robert T} and Natarajan Raghunand",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.tranon.2016.04.007",
language = "English (US)",
volume = "9",
pages = "228--235",
journal = "Translational Oncology",
issn = "1936-5233",
publisher = "Neoplasia Press",
number = "3",

}

TY - JOUR

T1 - Magnetic resonance imaging identifies differential response to pro-oxidant chemotherapy in a xenograft model

AU - Landowski, Terry H

AU - Guntle, Gerald P.

AU - Zhao, Dezheng

AU - Jagadish, Bhumasamudram

AU - Mash, Eugene A

AU - Dorr, Robert T

AU - Raghunand, Natarajan

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Induction of oxidative stress is a key component of cancer therapy. Pro-oxidant drugs have been demonstrated to enhance the efficacy of radiotherapy and chemotherapy. An emerging concept is that therapeutic outcomes are dictated by the differential redox buffering reserve in subpopulations of malignant cells, indicating the need for noninvasive biomarkers of tumor redox that can be used for dose identification and response assessment in a longitudinal setting. Magnetic resonance imaging (MRI) enhanced with the thiol-binding contrast agent Gd-LC6-SH, and hemodynamic response imaging (HRI) in combination with hypercapnia and hyperoxia were investigated as biomarkers of the pharmacodynamics of the small molecule pro-oxidant imexon (IMX). Human multiple myeloma cell lines 8226/S and an IMX-resistant variant, 8226/IM10, were established as contralateral tumors in SCID mice. T1slope, an MRI measure of the washout rate of Gd-LC6-SH, was significantly lower post-IMX therapy in 8226/S tumors compared with vehicle controls, indicating treatment-related oxidization of the tumor microenvironment, which was confirmed by analysis of tumor tissue for thiols. T1slope and ex vivo assays for thiols both indicated a more reduced microenvironment in 8226/IM10 tumors following IMX therapy. HRI with hypercapnia challenge revealed IMX inhibition of vascular dilation in 8226/S tumors but not 8226/IM10 tumors, consistent with decreased immunohistochemical staining for smooth muscle actin in treated 8226/S tumors. MRI enhanced with Gd-LC6-SH, and HRI coupled with a hypercapnic challenge provide noninvasive biomarkers of tumor response to the redox modulator imexon.

AB - Induction of oxidative stress is a key component of cancer therapy. Pro-oxidant drugs have been demonstrated to enhance the efficacy of radiotherapy and chemotherapy. An emerging concept is that therapeutic outcomes are dictated by the differential redox buffering reserve in subpopulations of malignant cells, indicating the need for noninvasive biomarkers of tumor redox that can be used for dose identification and response assessment in a longitudinal setting. Magnetic resonance imaging (MRI) enhanced with the thiol-binding contrast agent Gd-LC6-SH, and hemodynamic response imaging (HRI) in combination with hypercapnia and hyperoxia were investigated as biomarkers of the pharmacodynamics of the small molecule pro-oxidant imexon (IMX). Human multiple myeloma cell lines 8226/S and an IMX-resistant variant, 8226/IM10, were established as contralateral tumors in SCID mice. T1slope, an MRI measure of the washout rate of Gd-LC6-SH, was significantly lower post-IMX therapy in 8226/S tumors compared with vehicle controls, indicating treatment-related oxidization of the tumor microenvironment, which was confirmed by analysis of tumor tissue for thiols. T1slope and ex vivo assays for thiols both indicated a more reduced microenvironment in 8226/IM10 tumors following IMX therapy. HRI with hypercapnia challenge revealed IMX inhibition of vascular dilation in 8226/S tumors but not 8226/IM10 tumors, consistent with decreased immunohistochemical staining for smooth muscle actin in treated 8226/S tumors. MRI enhanced with Gd-LC6-SH, and HRI coupled with a hypercapnic challenge provide noninvasive biomarkers of tumor response to the redox modulator imexon.

UR - http://www.scopus.com/inward/record.url?scp=84973110922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973110922&partnerID=8YFLogxK

U2 - 10.1016/j.tranon.2016.04.007

DO - 10.1016/j.tranon.2016.04.007

M3 - Article

AN - SCOPUS:84973110922

VL - 9

SP - 228

EP - 235

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

IS - 3

ER -